Entrada Therapeutics Reports Decrease in Collaboration Revenue and Net Loss for Q2 2026

Entrada Therapeutics, Inc. reported its financial results for the second quarter of 2026, revealing a collaboration revenue of $0.9 million, a significant decrease from $2.0 million in the same period last year. For the six months ending June 30, 2026, total collaboration revenue was $1.8 million, down from $22.5 million in the prior year. The decline in revenue is attributed to the completion of research activities under the Vertex Agreement, which had previously contributed substantial revenue. The company incurred a net loss of $42.8 million for the quarter, slightly improved from a loss of $42.9 million in the same quarter of 2025. For the first half of 2026, the net loss was $82.5 million, compared to $60.5 million in the prior year.

Operating expenses for the second quarter totaled $45.9 million, down from $48.8 million in the same period last year. Research and development expenses decreased to $35.4 million from $37.9 million, primarily due to reduced personnel and facility-related costs. General and administrative expenses also saw a slight decline, totaling $10.5 million compared to $10.9 million in the previous year. The company reported interest and other income of $2.2 million, down from $3.9 million, reflecting changes in interest earned from marketable securities.

In terms of operational developments, Entrada continues to advance its clinical programs, particularly in Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1). The company is actively conducting clinical trials for its lead candidates, ENTR-601-44 and ENTR-601-45, with expectations to report additional data by the end of 2026 and into 2027. The Vertex collaboration remains a key strategic partnership, with Vertex expected to share results from their ongoing trials in the second half of 2026.

As of June 30, 2026, Entrada had cash, cash equivalents, and marketable securities totaling $223.0 million, which the company believes will be sufficient to fund operations for at least the next 12 months. However, the company anticipates needing additional financing to support its ongoing research and development efforts, as it continues to incur significant operating losses. The outlook remains cautious, with the company acknowledging the risks associated with clinical development and the need for substantial capital to achieve its strategic goals.